{
    "code": "52028134",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52028134",
    "time": "2022-03-25 05:24:40",
    "許可證字號": "衛部藥輸字第028134號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/07\/21",
    "發證\/登錄日期": "110\/07\/21",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202813407",
    "中文品名": "畢得平凍晶注射劑",
    "英文品名": "Bendamustine Mylan",
    "適應症": "1.Binet分類stage B及C之慢性淋巴球白血病(chronic lymphocytic leukemia, CLL)。2.曾接受至少一種化療之和緩性非何杰金氏淋巴瘤，六個月內曾以rituximab治療失敗之單一治療。3.Bendamustine合併Rituximab適用於先前未曾接受治療的CD20陽性、第III\/IV期和緩性非何杰金氏淋巴癌(non-hodgkin lymphoma, NHL)。Bendamustine合併Rituximab適用於先前未曾接受治療且不適合自體幹細胞移植的第III\/IV期被套細胞淋巴癌(mantle cell lymphoma, MCL)。",
    "劑型": "243凍晶注射劑",
    "包裝": "25毫克、100毫克玻璃小瓶裝 每盒100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "監視期滿學名藥",
    "監視期限": "",
    "主成分略述": "BENDAMUSTINE HYDROCHLORIDE",
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "6201118216  台灣邁蘭有限公司",
    "申請商地址": "臺北市信義區信義路５段7號27樓",
    "主製造廠": [
        {
            "": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1004002510",
            "成分名稱": "BENDAMUSTINE HYDROCHLORIDE",
            "含量描述": "Bendamustine Hydrochloride Monohydrate (eq. to Bendamustine.....22.7mg)",
            "含量": "25.0000000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "1004002510",
            "成分名稱": "BENDAMUSTINE HYDROCHLORIDE",
            "含量描述": "Bendamusting Hydrochloride Monohydrate (eq. to Bendamustine.....90.8mg)",
            "含量": "100.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "3.2_藥物外觀_100mg-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=002&Type=10"
        },
        {
            "title": "3.1_藥物外觀_25 mg-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "1.1_Bendamustine Mylan PI_20210729-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=001&Type=9"
        },
        {
            "title": "1.3_Bendamustine 100mg vial Label_20210808-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=004&Type=8"
        },
        {
            "title": "1.3_Bendamustine 100mg vial Carton_20210808-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=003&Type=8"
        },
        {
            "title": "1.2_Bendamustine 25mg vial Label_20210808-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=002&Type=8"
        },
        {
            "title": "1.2_Bendamustine 25mg vial Carton_20210808-110-08-11.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52028134&Seq=001&Type=8"
        }
    ]
}